Laser Immunotherapy is an experimental treatment modality for
late-stage, metastatic tumors, which targets
solid primary and/or secondary tumors and utilizes an autologous vaccine-like approach to stimulate immune
responses. Specifically, laser immunotherapy combines laser-induced in situ tumor devitalization with an
immunoadjuvant for local immunostimulation. Here we report the initial results from a human breast
cancer pilot trial with laser immunotherapy. Six stage III and IV cancer patients were treated, all of which
were considered to be out of all other options, and preliminary data at the three-month examination are
presented. The immediate goal of the trial was to determine the patient tolerance and the toxicity of the
therapy, the optimal dose for the alteration of the course of the disease, and the reduction of the tumor
burden. Each patient was individually evaluated for toxicity tolerance through physical exams and by
appropriate supplemental and routine laboratory tests. Observable tumors in patients were followed with
physical examination and radiological evaluations. Treatment efficacy was judged by the size and number
of local and distant metastases before and after treatment.
|